FONAR Announces 3rd Quarter Fiscal 2011 Financial Results

Net Income Surpasses $1 Million for 2nd Straight Quarter

FONAR Corporation (NASDAQ:FONR), today announced its earnings for the third quarter of fiscal 2011, ended March 31, 2011. The Company has net income for the past four quarters and net income from operations for the past five quarters.

Statement of Operations Items

For the quarter ended March 31, 2011, net income was $1.2 million and income from operations was $1.4 million. This is compared to the same period ended March 31, 2010, when the net loss was $8,000 and income from operations was $25,000. (For a Chart visit: www.fonar.com/news/051011.htm).

Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results

PRO-DEX, INC. (Nasdaq:PDEX ) today announced financial results for its fiscal third quarter and nine months ended March 31, 2011.

Sales for the quarter ended March 31, 2011 were $7.6 million, 24% higher than sales of $6.2 million for the corresponding quarter in 2010.  For the nine months ended March 31, 2011, sales were $19.6 million, 12% higher than sales of $17.5 million for the corresponding period in 2010.  These results for both the quarter and the nine-month periods were due primarily to increases in sales of the Company's medical device products to its two largest customers, with the nine-month period also benefitting from growth in sales of the Company's motion control products.  

Endo Announces Agreement to Acquire American Medical Systems for $2.9 Billion

Furthers Endo's evolution from a product-driven company to a healthcare solutions provider
Strengthens Endo's leading core urology franchise while diversifying revenue, earnings and cash flow
Fulfills Endo's strategy to build scale in devices and services business segment
Transaction expected to be immediately accretive to adjusted diluted earnings per share upon close and accretive by $0.60 in 2012

Endo Pharmaceuticals (Nasdaq: ENDP) and American Medical Systems (AMS) (Nasdaq: AMMD) announced today that they have entered into a definitive agreement under which Endo will acquire AMS, a leading provider of world-class devices and therapies for male and female pelvic health, for $30 per share, or $2.9 billion in cash, which includes the assumption and repayment of $312 million of AMS debt.

TranS1 Inc. Announces AxiaLIF 1L+ 510(k) FDA Clearance

TranS1 Inc. (Nasdaq:TSON), a pioneer in minimally invasive approaches to lumbar spine surgery, today announced the 510(k) clearance of the AxiaLIF(R) 1L+ product line, an instrumentation and implant system for L5-S1 lumbar fusion.

The AxiaLIF 1L+ system represents the next generation of the original AxiaLIF 1L system first launched in 2005 that has a clinical history of over 10,000 implants. TranS1 will commence a limited market release immediately with the new implant and instrumentation and anticipates full commercial release in the second half of 2011.